A new Phase 1 clinical trial for celiac disease has just begun dosing patients. This trial is being run by Anokion SA.
Celiac Disease
Celiac disease is an autoimmune condition which causes damage to the small intestine. Symptoms of the disease vary from patient to patient. Many experience abdominal pain, nausea, vomiting, and diarrhea. More severe symptoms range from weight loss, reproductive issues, osteoporosis, and neurological problems. These symptoms affect patients long-term and unfortunately they don’t have many options in terms of treatment.
Celiac disease patients are instructed to follow a strict diet which is gluten free. By limiting their exposure to both gluten and gluten proteins, they can minimize their symptoms. However, this diet is often not enough for most patients.
It’s clear new options are needed.
The New Trial
This is a multi-center trial examining the effect of KAN-101 in celiac disease patients.
KAN-101 works by targeting the natural immune pathways in the liver. Researchers are hopeful that it could be an effective option for patients, significantly improving their quality of life.
This study is placebo-controlled and double-blind. Patients will be randomized to receive either the treatment or placebo. It is the very first investigation to evaluate this treatment for celiac disease patients who are currently on the typically prescribed diet. Every participant will be given a singular dose of the treatment across 4 cohorts with ascending doses or they will be given KAN-101 or the placebo treatment across 3 cohorts with ascending doses. The safety and tolerability of the therapy will also be evaluated.
Researchers expect to release the preliminary results from this trial within this year.
You can read more about this new trial here.
